SynthesisBMC cancer2022

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.

Mirko Fillbrunn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.